JP2008501753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008501753A5 JP2008501753A5 JP2007526295A JP2007526295A JP2008501753A5 JP 2008501753 A5 JP2008501753 A5 JP 2008501753A5 JP 2007526295 A JP2007526295 A JP 2007526295A JP 2007526295 A JP2007526295 A JP 2007526295A JP 2008501753 A5 JP2008501753 A5 JP 2008501753A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical composition
- lower alkyl
- composition according
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 15
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- -1 methylpyrrolyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 206010034580 Peripheral motor neuropathy Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000005545 motor peripheral neuropathy Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- XCVDGQBGMARFRY-GFCCVEGCSA-N (2r)-2-acetamido-n-[(3-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC(F)=C1 XCVDGQBGMARFRY-GFCCVEGCSA-N 0.000 claims 1
- PVNGTPGYSFGJIH-GFCCVEGCSA-N (2r)-2-acetamido-n-[(4-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=C(F)C=C1 PVNGTPGYSFGJIH-GFCCVEGCSA-N 0.000 claims 1
- SGBCQENKTXKIRD-MRXNPFEDSA-N (2r)-2-acetamido-n-benzyl-2-phenylacetamide Chemical compound O=C([C@H](NC(=O)C)C=1C=CC=CC=1)NCC1=CC=CC=C1 SGBCQENKTXKIRD-MRXNPFEDSA-N 0.000 claims 1
- 101100149686 Caenorhabditis elegans snr-4 gene Proteins 0.000 claims 1
- 101100478234 Caenorhabditis elegans spr-4 gene Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000003700 epoxy group Chemical group 0.000 claims 1
- 125000003838 furazanyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57806304P | 2004-06-09 | 2004-06-09 | |
| EP04013636A EP1604656A1 (en) | 2004-06-09 | 2004-06-09 | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| PCT/EP2005/006169 WO2005120476A2 (en) | 2004-06-09 | 2005-06-08 | Novel use of peptide compounds for treating amyotrophic lateral sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008501753A JP2008501753A (ja) | 2008-01-24 |
| JP2008501753A5 true JP2008501753A5 (https=) | 2008-04-17 |
Family
ID=34925316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007526295A Withdrawn JP2008501753A (ja) | 2004-06-09 | 2005-06-08 | 筋萎縮性側索硬化症治療用ペプチド化合物の新規な用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20050277596A1 (https=) |
| EP (2) | EP1604656A1 (https=) |
| JP (1) | JP2008501753A (https=) |
| CN (1) | CN1960720A (https=) |
| AT (1) | ATE544449T1 (https=) |
| AU (1) | AU2005251459A1 (https=) |
| BR (1) | BRPI0511875A (https=) |
| CA (1) | CA2565102A1 (https=) |
| EA (1) | EA200602220A1 (https=) |
| MX (1) | MXPA06014194A (https=) |
| TW (1) | TW200701984A (https=) |
| UA (1) | UA87843C2 (https=) |
| WO (1) | WO2005120476A2 (https=) |
| ZA (1) | ZA200608594B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1243262T3 (da) * | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
| ES2185606T3 (es) | 2001-03-21 | 2003-05-01 | Sanol Arznei Schwarz Gmbh | Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma. |
| JP4664924B2 (ja) * | 2003-12-02 | 2011-04-06 | ウーツェーベー ファルマ ゲーエムベーハー | 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用 |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| EP1579858A1 (en) * | 2004-03-26 | 2005-09-28 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| KR20070007931A (ko) | 2004-04-16 | 2007-01-16 | 쉬바르츠파르마에이지 | 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도 |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| EP1604655A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| PL1781276T3 (pl) * | 2004-08-27 | 2010-11-30 | Ucb Pharma Gmbh | Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy |
| EP1642889A1 (en) * | 2004-10-02 | 2006-04-05 | Schwarz Pharma Ag | Improved synthesis scheme for lacosamide |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| US7902401B2 (en) * | 2006-12-14 | 2011-03-08 | Nps Pharmaceuticals, Inc. | Fluorinated compounds |
| EP1873527A1 (en) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Method for identifying CRMP modulators |
| CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| WO2007144195A2 (en) | 2006-06-15 | 2007-12-21 | Schwarz Pharma Ag | Pharmaceutical composition with synergistic anticonvulsant effect |
| CA2672494A1 (en) * | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
| EP2214657A1 (en) | 2007-10-23 | 2010-08-11 | UCB Pharma GmbH | Compounds for treating demyelination conditions |
| CA2774569A1 (en) * | 2009-09-23 | 2011-03-31 | The University Of North Carolina At Chapel Hill | Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| WO2011101863A2 (en) | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of lacosamide |
| MX2013005974A (es) | 2010-12-02 | 2013-07-29 | Ucb Pharma Gmbh | Formulacion de lacosamida de administracion una vez al dia. |
| EP2468261A1 (en) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
| CN109069480A (zh) | 2015-12-30 | 2018-12-21 | 阿达玛斯医药公司 | 用于治疗与癫痫相关的病症的方法和组合物 |
| US11278634B1 (en) | 2021-02-12 | 2022-03-22 | Extrovis Ag | Stable parenteral composition of lacosamide |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US277596A (en) * | 1883-05-15 | Top-prop nut | ||
| US261204A (en) * | 1882-07-18 | Joel gadbuey | ||
| US227961A (en) * | 1880-05-25 | Envelope-fastener | ||
| US101582A (en) * | 1870-04-05 | Improved refrigerator | ||
| DE2413125C2 (de) | 1974-03-15 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Indolylacetylaminosäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneipräparate |
| DE2627069A1 (de) | 1975-06-19 | 1977-01-20 | Ajinomoto Kk | Verfahren zur herstellung von substituierten schwefelhaltigen l-aminosaeuren |
| DE2735537A1 (de) | 1977-08-06 | 1979-02-22 | Troponwerke Gmbh & Co Kg | Indolacetoxyacetylaminosaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPS557242A (en) | 1978-06-30 | 1980-01-19 | Tanabe Seiyaku Co Ltd | Phenethylamine derivative |
| FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| FR2489319A1 (fr) | 1980-08-27 | 1982-03-05 | Clin Midy | Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant |
| DE3134933A1 (de) | 1981-09-03 | 1983-03-31 | Hoechst Ag, 6230 Frankfurt | "harnstoffderivate, verfahren zu ihrer herstellung und diese enthaltende medikamente sowie deren verwendung" |
| US5378729A (en) | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| EP0194464B1 (en) | 1985-02-15 | 1991-04-03 | Research Corporation Technologies, Inc. (a Delaware corp.) | Amino acid derivatives and use thereof for the preparation of an anticonvulsant |
| JPS61242589A (ja) | 1985-04-22 | 1986-10-28 | Mitsui Toatsu Chem Inc | Ｌ−含硫アミノ酸の製造方法 |
| PH24782A (en) | 1985-10-24 | 1990-10-30 | Sankyo Co | Composition containing a penem or carbapenem antibiotic and the use of the same |
| NZ222045A (en) | 1986-08-21 | 1989-10-27 | Res Corp Technologies Inc | From diamides up to tetrapeptides for use as anticanvulsants |
| CA2056911C (en) | 1990-12-11 | 1998-09-22 | Yuuichi Nagano | Hiv protease inhibitors |
| AU685768B2 (en) | 1992-12-11 | 1998-01-29 | Novartis Ag | Benzazepinone derivatives |
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| EP0840612A1 (en) | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| GB9601724D0 (en) | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| US5773475A (en) * | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| DE19614533A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung |
| DE19614534A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| US6277825B1 (en) | 1996-07-22 | 2001-08-21 | University Of Utah Research Foundation | Use of conantokins for treating pain |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| DE19636046A1 (de) | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6048899A (en) * | 1997-03-17 | 2000-04-11 | Research Corporation Tech., Inc. | Anticonvulsant enantiomeric amino acid derivatives |
| AU7937298A (en) | 1997-07-08 | 1999-02-08 | Ono Pharmaceutical Co. Ltd. | Amino acid derivatives |
| DE19743140A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19743142A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19744799A1 (de) | 1997-10-10 | 1999-04-15 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| WO1999023078A2 (de) | 1997-10-31 | 1999-05-14 | Basf Aktiengesellschaft | Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten |
| EP1073432B1 (en) | 1998-04-14 | 2007-08-15 | The General Hospital Corporation | Use of d-serine or d-alanine for treating schizophrenia |
| GB9816228D0 (en) | 1998-07-24 | 1998-09-23 | Pfizer Ltd | Isoquinolines |
| DE10029014A1 (de) | 2000-06-15 | 2001-12-20 | Univ Schiller Jena | Urokinase-Hemmstoffe |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| AU2002224847A1 (en) | 2000-11-21 | 2002-06-03 | U C B, S.A. | N-alkylated gaba compounds, processes for their preparation and their use as medicaments |
| DK1243262T3 (da) * | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
| ES2185606T3 (es) | 2001-03-21 | 2003-05-01 | Sanol Arznei Schwarz Gmbh | Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma. |
| CA2445290A1 (en) | 2001-04-26 | 2002-11-07 | Chenkou Wei | A pharmaceutical tablet having a high api content |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| DE10326303A1 (de) | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
| US20050227961A1 (en) | 2004-04-08 | 2005-10-13 | Vela Pharmaceuticals, Inc. | Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome |
| EP1604654A1 (en) | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating dyskinesia |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
-
2004
- 2004-06-09 EP EP04013636A patent/EP1604656A1/en not_active Withdrawn
-
2005
- 2005-06-07 US US11/145,965 patent/US20050277596A1/en not_active Abandoned
- 2005-06-08 CA CA002565102A patent/CA2565102A1/en not_active Abandoned
- 2005-06-08 CN CNA2005800174638A patent/CN1960720A/zh active Pending
- 2005-06-08 UA UAA200612858A patent/UA87843C2/ru unknown
- 2005-06-08 AT AT05750352T patent/ATE544449T1/de active
- 2005-06-08 WO PCT/EP2005/006169 patent/WO2005120476A2/en not_active Ceased
- 2005-06-08 JP JP2007526295A patent/JP2008501753A/ja not_active Withdrawn
- 2005-06-08 EA EA200602220A patent/EA200602220A1/ru unknown
- 2005-06-08 BR BRPI0511875-1A patent/BRPI0511875A/pt not_active IP Right Cessation
- 2005-06-08 MX MXPA06014194A patent/MXPA06014194A/es not_active Application Discontinuation
- 2005-06-08 EP EP05750352A patent/EP1755577B1/en not_active Expired - Lifetime
- 2005-06-08 AU AU2005251459A patent/AU2005251459A1/en not_active Abandoned
- 2005-07-11 TW TW094123424A patent/TW200701984A/zh unknown
-
2006
- 2006-10-13 ZA ZA200608594A patent/ZA200608594B/en unknown
-
2008
- 2008-09-18 US US12/212,864 patent/US7718161B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008501753A5 (https=) | ||
| JP2008501760A5 (https=) | ||
| JP2007530493A5 (https=) | ||
| JP2008503533A5 (https=) | ||
| JP2007532607A5 (https=) | ||
| CA2566301A1 (en) | Novel use of peptide compounds for treating essential tremor and other tremor syndromes | |
| JP2008510758A5 (https=) | ||
| JP2004519469A5 (https=) | ||
| JP2002521428A5 (https=) | ||
| JP2009102342A5 (https=) | ||
| JP2006504795A5 (https=) | ||
| JP2021504313A (ja) | 慢性炎症性疾患および／または自己免疫疾患の予防または治療における使用のためのビドフルジムス（Ｖｉｄｏｆｌｕｄｉｍｕｓ）の投与レジメン | |
| JP2014516942A5 (https=) | ||
| JP2008501753A (ja) | 筋萎縮性側索硬化症治療用ペプチド化合物の新規な用途 | |
| JP2012515184A5 (https=) | ||
| US20230000866A1 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| JP2010540519A5 (https=) | ||
| JP2021519764A5 (https=) | ||
| JP2007502832A5 (https=) | ||
| JP2010514834A5 (https=) | ||
| JP2011046708A5 (https=) | ||
| JP2004529207A5 (https=) | ||
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| WO2016203468A1 (en) | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof | |
| EP1461025B1 (en) | Treatment of parkinson's disease with cape |